GLP-1 review reduces heart attack, stroke risk

Anglia Ruskin University researchers said this week that a review of long-term cardiovascular outcome trials found GLP-1 receptor agonists reduced the risk of heart attack, stroke, heart failure and premature death in adults treated for obesity or type 2 diabetes. The study summary was published by ScienceDaily on May 20, and the underlying paper appeared on April 30 in *Cardiovascular Diabetology – Endocrinology Reports*. The authors said the analysis covered large randomized trials of drugs in the GLP-1 class, including medicines sold as Ozempic and Wegovy. They said the benefits extended beyond weight loss and blood-sugar control to major cardiovascular outcomes. ### Which drugs were included in the review? The paper reviewed GLP-1 receptor agonists, a class that includes semaglutide and liraglutide, according to the study summary and the journal article. Semaglutide is marketed by Novo Nordisk as Ozempic for diabetes and Wegovy for obesity, while liraglutide has been sold as Victoza and Saxenda. The review focused on cardiovascular outcome trials designed to test whether these medicines affect rates of major events such as heart attack and stroke over time. (sciencedaily.com) ### What did the researchers say they found? The authors said the evidence showed “significant” reductions in heart attacks, strokes, heart failure and premature death over the long term. ScienceDaily’s summary said the review drew on international trial data and found cardiovascular protection lasting up to 2.7 years. The paper described itself as a synthesis of long-term cardiovascular safety and efficacy data in high-risk populations using GLP-1 receptor agonists. (sciencedaily.com) ### How does this fit with earlier GLP-1 heart data? Nature Medicine published a separate review in 2026 stating that GLP-1 receptor agonists reduce major cardiovascular outcomes, including non-fatal myocardial infarction, stroke and cardiovascular death. That broader literature review said the class had moved from diabetes treatment into a wider role spanning obesity, cardiovascular disease and kidney disease. The Anglia Ruskin-led paper adds another synthesis focused on long-term trial evidence and cardiovascular endpoints. (sciencedaily.com) ### Does this mean the drugs protect everyone who takes them? The review did not say that every patient gets the same benefit. The journal paper said the evidence came from cardiovascular outcome trials in high-risk populations, and those studies typically enroll people with obesity, type 2 diabetes, established cardiovascular disease, or combinations of those conditions. The findings support benefit in the populations studied, rather than serving as a blanket result for all adults seeking weight loss. (nature.com) ### Why are researchers emphasizing “long-term” outcomes? The authors said one concern for patients considering GLP-1 drugs is what happens with prolonged use. Their review was framed as a long-term assessment of both safety and efficacy, using trials that tracked major cardiovascular events over extended follow-up. ScienceDaily’s summary said the drugs could become a “major weapon” against cardiovascular disease as well as obesity and diabetes, attributing that view to the researchers. (link.springer.com) ### What comes next for this evidence? The April 30 paper is now part of a larger body of GLP-1 cardiovascular research that continues to grow in 2026. Clinicians and guideline writers will weigh this review alongside individual randomized trials and other meta-analyses, including newer work in *Nature Medicine* and cardiovascular journals. For readers looking for the source material, the two key dates are April 30, 2026, for the journal publication and May 20, 2026, for the ScienceDaily summary. (sciencedaily.com) (link.springer.com)